# Lifecore Biomedical, Inc. (LFCR)

> Source: Nexqual · https://nexqual.com/LFCR · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Lifecore Biomedical, Inc. (LFCR), nexqual.com/LFCR" · informational, not investment advice.

**Price:** USD 6.44 (+0.31% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 6.42 · day 6.43–6.48 · 52w 3.63–8.98 · market cap $244M · NMS

## Key facts
- Analysts: Hold (mean 3.00 on a 1–5 scale) (4 analysts), mean target USD 6.28 (range 6.28–6.28).
- Total return with dividends: 1Y -1.4% vs S&P 500 +18.1%; 5Y -34.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-03, EPS estimate USD -0.31, revenue estimate $25.5M.

## Analysts
Consensus Hold (mean 3.00 on a 1–5 scale), 4 analysts; mean target USD 6.28 (low 6.28, high 6.28).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Barrington Research | Downgrade | Outperform → Market Perform |  |
| 2026-09-28 | William Blair | Downgrade | Outperform → Market Perform |  |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -1.4% | -34.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -1.4% | -8.1% |
| Volatility (annualized) | 77.1% | 84.9% |
| Max drawdown | -58.5% (Jan 2026→Mar 2026) | -85.9% (Feb 2022→Mar 2023) |

## Peers (Drug Manufacturers - Specialty & Generic)
BHC (Bausch Health Companies Inc.) USD 6.31 +7.13% · HCM (HUTCHMED (China) Limited) USD 13.94 +3.26% · LQDA (Liquidia Corporation) USD 34.78 +29.73% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.65 +2.98% · INDV (Indivior Pharmaceuticals, Inc.) USD 33.62 -5.08% · RGC (Regencell Bioscience Holdings L) USD 9.52 +16.24%

## More
Full page: https://nexqual.com/LFCR · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt